The Future of GLP-1: New Drugs Coming in 2026
Medically Reviewed by
Board Certified Endocrinologist
Published
Mar 10, 2026
Last Reviewed
Mar 14, 2026
Sources
5 peer-reviewed
Standard
YMYL / E-E-A-T
The Current Landscape
Two drugs currently define the GLP-1 market: semaglutide (Ozempic/Wegovy from Novo Nordisk) and tirzepatide (Mounjaro/Zepbound from Eli Lilly). Between them, they've set efficacy benchmarks that would have seemed implausible five years ago — 15–17% weight loss for semaglutide and up to 22% for tirzepatide. For a grounding in how these medications work, our GLP-1 fundamentals guide covers the mechanism. What matters for the pipeline discussion is where the ceiling sits now, because the incoming drugs are competing to push past it.
The Shift to Oral Medications
The biggest near-term shift is the development of highly effective oral GLP-1 medications. While oral semaglutide (Rybelsus) exists, new daily pills in late-stage trials aim to deliver results comparable to injectables. For those comparing current injectable options, our Ozempic vs Wegovy comparison remains a useful benchmark for what oral drugs will need to outperform.
Triple Agonists (GLP-1/GIP/Glucagon)
Researchers are testing 'triple G' receptor agonists that target three different hormone receptors simultaneously. Early clinical trial data suggests these could yield unprecedented weight loss results, potentially exceeding 25% of total body weight, bridging the gap between medical therapy and bariatric surgery. Eli Lilly's retatrutide showed 24.2% body weight loss at 48 weeks in Phase 2 — the highest number ever recorded in a pharmacological weight loss trial.
Focus on Muscle Preservation
A major criticism of current GLP-1s is the concurrent loss of lean muscle mass — roughly 25–40% of total weight lost can be from lean tissue. The class of drugs arriving in 2026 includes combination therapies designed to actively preserve or even build muscle mass while stripping away fat. Amgen's MariTide (bimagrumab), used in combination with GLP-1 therapy, has shown the ability to selectively reduce fat while preserving lean muscle mass.
Frequently Asked Questions
These answers are for informational purposes only. Always consult your physician for personalized medical advice.
Was this article helpful?
Scientific References & Further Reading
- Wilding JPH et al. — Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021.
- Jastreboff AM et al. — Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022.
- FDA Drug Approvals Database — GLP-1 Receptor Agonists. U.S. Food & Drug Administration.
- PubMed — GLP-1 Receptor Agonist Research Index. National Library of Medicine.
- Mayo Clinic — Semaglutide (GLP-1 Agonist): Uses, Side Effects, and Dosing. Mayo Clinic Drug Reference.
This content is produced in accordance with GLP-1 Health's editorial standards and is based on peer-reviewed clinical evidence from the sources cited above. It does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.
